Success Stories: A Principal Investigator in Oncology from China Obtains NIW Confirmation Without RFE, Thanks to Our Team’s Effort
Client’s Testimonial:
“Thank you for all your efforts on my I-140 NIW approval.”
On April 13th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for a Principal Investigator in the Field of Oncology (Approval Notice).
General Field: Oncology
Position at the Time of Case Filing: Principal Investigator
Country of Origin: China
Country of Residence at the Time of Filing: China
Approval Notice Date: April 13th, 2022
Processing Time: 18 months, 22 days
Case Summary:
“[The client’s] research on detecting gastric cancer early is relevant to improving public health outcomes as a whole. One of the most effective ways to reduce cancer mortality is early detection, which comprises both early diagnosis and screening for certain risk factors which carry a higher risk of causing a person to develop cancer. As one of the most prominent researchers in this area, [the client] has considerably increased awareness of these new tools, strengthening research throughout the scientific community. When this is taken into consideration with the practical value of her research, clearly [the client’s] work is of great value to oncology and the medical field as a whole.”
“[The client] is one of the most prolific researchers working in the area of oncology today. This assertion is evidenced by the success of her research efforts related to leukemia, as well as the direct applications of her work. Supporting [the client’s] research presence in the United States is vital in order to remain a world leader in studying more advanced leukemia treatments.”
As is evident from the above statements the support given to our client in these testimonials is very clear about the merit and significance of her work in the field. Our client hailed from China and needed our help with her NIW (National Interest Waiver) petition. The two passages above are drawn from a longer letter written in her favor by other experts in oncology.
As an expert in the field herself, she has been working in this area for the past 8 years. And we also soon found that her proposed endeavor was to work on applying CRISPR and exosome encapsulation techniques to regulate genes that target leukemia in order to discover novel therapeutic targets for acute lymphoblastic leukemia. We immediately knew that her research was of great importance because it aids in the global fight against cancer. Her research was also directly aligned with the interests of the United States.
We made certain of her NIW victory by also saying that she was academically active and her work has resulted in 15 peer-reviewed journal articles (3 of them first-authored) which have been cited a total of 120 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of oncology. From these citations, it is evident that her peers have recognized the value of her work. Additionally, the National Natural Science Foundation of China provided funding for her work. She has also been invited to conduct reviews for other magazines some 4 times already indicating that she is considered an experienced researcher in the area.
On the other hand, she had 4 letters of recommendation supporting her claims to the NIW category, and thus in spite of her application getting an RFE on reaching the adjudication panel, she received her approval albeit a little delayed.
We are confident that she will continue to be an asset to the country and her work shall prove beneficial for the public in the U.S. We wish her all the best in any future endeavors she may take up ahead.